ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies designed to overcome resistance mechanisms that limit the durability of cancer treatments. Its pipeline targets oncogenic pathways and tumor adaptations that allow cancers to escape standard targeted therapies, hormone therapies, or other regimens. The company works primarily in oncology drug discovery and development for patients whose disease has progressed or is expected to progress on existing agents.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -30 | — |
| Q2 2025 | 0 | — | -36.4 | — |
| Q3 2025 | 0 | — | -32.6 | — |
| Q4 2025 | 0 | — | -30.5 | — |
| Q1 2026 | 0 | — | -35.8 | — |
| Q2 2026 | 0 | — | -41.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Seneca Foods Corporation (SENEA), Westamerica Bancorporation (WABC), Willdan Group, Inc. (WLDN), Gibraltar Industries, Inc. (ROCK), Vor Biopharma Inc. (VOR), MeiraGTx Holdings plc (MGTX)